Navigation Links
Paul Pospisil Joins Korn/Ferry as Senior Client Partner in Biotechnology and Life Sciences Practice
Date:1/6/2011

NEW YORK, Jan. 6, 2011 /PRNewswire/ -- Korn/Ferry International (NYSE: KFY), a premier global provider of talent management solutions, today announced that Paul Pospisil, Ph.D. has joined the Firm as a Senior Client Partner in the Biotechnology and Life Sciences Practice.  He will be based out of the Firm's New York office.

Mr. Pospisil joins Korn/Ferry after serving more than 15 years as an investor and operating executive in the biotechnology industry.  He brings to the Firm strong experience in drug discovery and development, finance, business development, technology assessment and evaluation, and business strategy.

Throughout his career, Mr. Pospisil has held senior-level positions at widely-regarded consulting and venture capital firms, as well as leading globally-focused biotechnology and bio-pharmaceutical organizations.

"Paul's unique credentials as both an investor and biotechnology executive, coupled with his vast knowledge of the issues and trends driving the industry, will be a great fit for our entrepreneurial life sciences clients," said Stephen Israel, Korn/Ferry's managing director, biotechnology and pharmaceuticals.

Mr. Pospisil joins the Firm from Aduro Capital LLC, an investment management company focused on the public healthcare sector and Aduro Partners LLC, an advisory firm focused on helping venture-backed and public life science companies assess, evaluate, partner opportunities and build businesses.  Previously, he was a partner in life science investments at Atlas Venture and earlier was with Millennium Pharmaceuticals, where his last position was director, strategy leadership.  Earlier, he was a new product manager at Altus Biologics, a spin-out of Vertex Pharmaceuticals.

Mr. Pospisil received a Ph.D. in Organic Chemistry from Harvard University and a Bachelor of Arts in Biochemistry from New York University.  He also attended Harvard Business School's Program for Management Development (PMD).

About Korn/Ferry International

Korn/Ferry International, with a presence throughout the Americas, Asia Pacific, Europe, the Middle East and Africa, is a premier global provider of talent management solutions. Based in Los Angeles, the firm delivers an array of solutions that help clients to attract, develop, retain and sustain their talent. Visit www.kornferry.com for more information on the Korn/Ferry International family of companies, and www.kornferryinstitute.com for thought leadership, intellectual property and research.


'/>"/>
SOURCE Korn/Ferry International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
2. Dr. Russell L. Chapman Joins Aquatic Energy as the Chairman of its Science Advisory Board
3. Dr. Michael Hanley Joins Celtaxsys as CEO
4. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
5. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
6. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
7. Todd Park, Chief Technology Officer of U.S. Department of Health and Human Services, Joins Opening Keynote Line-Up at 2010 mHealth Summit
8. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
9. Excerpta Medica Joins Adelphi Worldwide
10. Philadelphia Eagles Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line
11. Christopher Bowe Joins Scrip as US Healthcare Analyst
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):